Related Experiment Video

Updated: Jun 14, 2025

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.2K

Impact of preS1 Evaluation in the Management of Chronic Hepatitis B Virus Infection

Yuka Hayashi1, Kazuto Tajiri1, Tatsuhiko Ozawa2,3

  • 1Third Department of Internal Medicine, Faculty of Medicine, Academic Assembly, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.

Medicina (Kaunas, Lithuania)
|August 29, 2024
PubMed

Insights

Hepatitis B surface antigen (HBsAg) measurement is key for chronic hepatitis B (CHB) management. This study shows preS1 protein expression is altered in CHB and is a promising therapeutic target.

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Hepatitis B surface antigen (HBsAg) measurement is crucial for managing chronic hepatitis B virus (CHB) infection.
  • HBsAg comprises large, middle, and small surface proteins, but individual evaluation is uncommon clinically.

Purpose of the Study:

  • To investigate preS1 protein expression and antigenicity in CHB patients.
  • To assess the role of preS1 in the HBV infection cycle and its potential as a therapeutic target.

Main Methods:

  • Utilized seven monoclonal antibodies (mAbs) to study preS1 expression in 68 CHB patients.
  • Examined the antigenicity of preS1 across different genotypes (Gts) A to D.

Main Results:

  • Monoclonal antibodies recognized preS1 across Gts A-D, with epitopes concentrated in the aa33-47 region.
  • An aa45F substitution significantly reduced preS1 antigenicity.
  • PreS1 expression remained consistent irrespective of HBsAg levels and Gts, unlike SHBs.

Conclusions:

  • The antigenic epitope of preS1 is conserved across different HBV genotypes.
  • PreS1 expression patterns are altered during CHB, indicating its critical role in the HBV lifecycle.
  • PreS1 emerges as a potential therapeutic target for CHB.

Keywords:
HB surface proteinHBV entryHBsAgmonoclonal antibodypreS1

More Related Videos

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

3.2K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.8K

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
77
Pleural Effusion II: Symptoms and Management01:28

Pleural Effusion II: Symptoms and Management

Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
158
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
45.8K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
34
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
57
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
111